Elitepain Lomps Court Case 2 Link

The contract required Lomps to:

In early 2023, ElitePain alleged that Lomps fell short of both the purchase minimum and the promotional targets, while also advertising PainX‑Pro as “non‑addictive” in a series of online ads—language that ElitePain contended was not supported by FDA labeling. elitepain lomps court case 2 link

| Item | Detail | |------|--------| | Case name | ElitePain, Inc. v. Lomps Healthcare LLC (Court Case No. 2) | | Jurisdiction | United States District Court for the Northern District of California (N.D. Cal.) | | Filing date | March 15 2024 | | Key issue | Alleged breach of a multi‑year supply‑and‑distribution agreement for prescription‑grade pain‑management medication. | | Outcome (as of latest filing) | Partial summary judgment granted to ElitePain on the breach‑of‑contract claim; litigation continues on the alleged false‑advertising claim. | | Why it matters | Sets a precedent for how “best‑efforts” supply clauses are interpreted in the pharmaceutical‑distribution sector and clarifies the evidentiary standards for false‑advertising claims under the Lanham Act. | The contract required Lomps to:

| Date | Event | |------|-------| | Mar 15 2024 | ElitePain filed the complaint in N.D. Cal. | | Apr 10 2024 | Lomps filed a Rule 12(b)(6) motion to dismiss, arguing the “best‑efforts” language is vague and the Lanham‑Act claim is pre‑empted by FDA regulation. | | Jun 3 2024 | Court granted a partial summary judgment on the breach‑of‑contract claim, finding Lomps’ purchase records fell short of the contractual threshold. | | Jun 10 2024 | The court denied Lomps’ motion to dismiss the Lanham‑Act claim, stating the “non‑addictive” language is not automatically pre‑empted because it is a marketing claim, not a label claim. | | Sep 15 2024 | Discovery deadline for initial document production. | | Oct 22 2024 | Trial on the false‑advertising claim scheduled (subject to possible settlement). | In early 2023, ElitePain alleged that Lomps fell

| Claim | Legal Basis | What ElitePain Said | |-------|-------------|---------------------| | Breach of Contract | California Commercial Code §§ 1723‑1725; the contract’s explicit purchase‑minimum clause. | Lomps failed to meet the $12 M yearly purchase floor for 2022 and 2023, and did not provide the required quarterly sales reports. | | False‑Advertising (Lanham Act) | 15 U.S.C. §§ 1125(a) (false or misleading description of goods). | Lomps’ online ads suggested PainX‑Pro was “non‑addictive,” which contradicted FDA labeling and misled consumers. | | Unfair Competition (California Business & Professions Code § 17200) | Unlawful, unfair, or fraudulent business practices. | The alleged misrepresentations gave Lomps an unfair advantage over rival distributors. |